1
|
Corazza I, Ceccarelli L, Moretti G, Tavoschi L, Vainieri M. Design of a care pathway for Hepatitis C: a pilot study with three University Hospitals from Tuscany. Eur J Public Health 2022. [DOI: 10.1093/eurpub/ckac131.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Monitoring and evaluation activities are recognised as key to quality improvement in healthcare performance. The present study is intended to design a performance evaluation system for care pathway for patients with chronic Hepatitis C virus (HCV) infection, to follow them along the continuum of care throughout regional healthcare services, from diagnosis to treatment course completion. Four phases of the care pathway, namely diagnosis, linkage to care, treatment, and outcome were identified. Each phase of the care pathway was populated by a set of observation and evaluation indicators. Data sources were: administrative health data from the Tuscany Regional Healthcare System; patient-reported experience and outcome measures collected by means of questionnaires administered by the health professionals during patients’ consultation in the three University Hospitals of the Tuscany Region. The availability of data, collected from the administrative flows and thanks to the active involvement of health professionals, showed the feasibility of designing a care pathway for HCV. More particularly, using administrative data, three performance indicators were calculated for the prevention phase, two for the linkage to care phase and two more for the treatment and outcome phases, respectively. Moreover, two indicators related to linkage to care and outcome phases were designed, but data require further investigation. On the other hand, using patient-reported experience data, four indicators can be calculated for the linkage to care phase, while regarding patient-reported outcomes, the feasibility of calculation depends on the number of patients that will be involved in follow-up visits. The care pathway designed may be useful to: identify shortcomings of the healthcare services for chronic HCV patients; foster quality improvement actions; inform allocation of resources to accelerate HCV elimination in Tuscany.
Key messages
• The authors propose a care pathway for Hepatitis C, consisting of four distinct phases, populated respectively with diagnosis, linkage to care, treatment, and outcome indicators.
• The care pathway can be used as a management tool for the identification of possible quality improvement actions to be undertaken with respect to the healthcare services provided to HCV patients.
Collapse
Affiliation(s)
- I Corazza
- Health and Management Laboratory, Sant'Anna School of Advanced Studies , Pisa, Italy
| | - L Ceccarelli
- Health and Management Laboratory, Sant'Anna School of Advanced Studies , Pisa, Italy
- Faculty of Medicine and Surgery, University of Pisa , Pisa, Italy
| | - G Moretti
- Health and Management Laboratory, Sant'Anna School of Advanced Studies , Pisa, Italy
| | - L Tavoschi
- Faculty of Medicine and Surgery, University of Pisa , Pisa, Italy
| | - M Vainieri
- Health and Management Laboratory, Sant'Anna School of Advanced Studies , Pisa, Italy
| |
Collapse
|
2
|
Bivona U, Costa A, Ciurli P, Donvito T, Lombardi G, Misici I, Moretti G, Caltagirone C, Formisano R, Prigatano GP. Modification of the Patient Competency Rating Scale to Measure Anosodiaphoria after Severe Acquired Brain Injury: Preliminary Findings. Arch Clin Neuropsychol 2021; 37:753-761. [PMID: 34933340 DOI: 10.1093/arclin/acab096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/30/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE Impaired self-awareness (ISA) of altered functional capacities is a common sequelae of severe acquired brain injury that can severely hamper neuro-rehabilitation in this clinical population. ISA is frequently associated with anosodiaphoria and/or apathy. Although several scales are available to measure apathy, no tools have been published to specifically assess anosodiaphoria after acquired brain injury. In this paper, we reported an initial effort to develop an anosodiaphoria subscale in a commonly used measure of ISA, that is, the Patient Competency Rating scale-neurorehabilitation form (PCRS-NR). METHOD A sample of 46 participants with severe acquired brain injury completed a functional, ISA, apathy, and anosodiaphoria assessment. One informal caregiver of each patient participated in the study. Thus, we were able to obtain external data on his/her level of functional competencies, and self-awareness, which allowed separating patients with low self-awareness (LSA) from those with high self-awareness (HSA). Finally, the patients were compared with 44 healthy age-gender-years of formal education matched control participants (HCs). RESULTS Compared to both patients with HSA and HCs, patients with LSA demonstrated greater anosodiapvhoria and lower levels of functioning than both HSA patients and HCs. A stronger relationship emerged between ISA and anosodiaphoria rather than with apathy. CONCLUSIONS These initial findings provide support that PCRS scale can be adapted to measure anosodiaphoria as well as ISA. The findings reveal a stronger correlation between this measure of anosodiaphoria and ISA compared with the correlation of apathy to ISA. The present method for measuring anosodiaphoria takes into account the actual levels of patients' functioning.
Collapse
Affiliation(s)
- U Bivona
- IRCCS, Santa Lucia Foundation, Neuroriabilitazione 2, Rome, Italy
| | - A Costa
- IRCCS, Santa Lucia Foundation, Rome, Italy.,Unicusano University, Rome, Italy
| | - P Ciurli
- IRCCS, Santa Lucia Foundation, Neuropsychology Unit, Rome, Italy
| | - T Donvito
- IRCCS, Santa Lucia Foundation, Neuroriabilitazione 2, Rome, Italy
| | - G Lombardi
- IRCCS, Santa Lucia Foundation, Neuroriabilitazione 2, Rome, Italy
| | - I Misici
- IRCCS, Santa Lucia Foundation, Neuroriabilitazione 2, Rome, Italy
| | - G Moretti
- IRCCS, Santa Lucia Foundation, Neuroriabilitazione 2, Rome, Italy
| | - C Caltagirone
- IRCCS, Santa Lucia Foundation, Neuropsychology Unit, Rome, Italy.,Tor Vergata University, Rome, USA
| | - R Formisano
- IRCCS, Santa Lucia Foundation, Neuroriabilitazione 2, Rome, Italy
| | - G P Prigatano
- Department of Clinical Neuropsychology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA
| |
Collapse
|
3
|
Scanferla M, Moretti G, Oldani D, Lomas G, Storelli S, Romeo E. Scanner intraorale e facciale, chirurgia guidata e carbonio. Il futuro dell’odontoiatria? Dental Cadmos 2021. [DOI: 10.19256/d.cadmos.2021.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
4
|
Dieci M, Griguolo G, Bisagni G, Musolino A, Spazzapan S, Moretti G, Schiavi F, Pinato C, Vernaci G, Giarratano T, Urso L, Tosi A, Magni G, Lo Mele M, De Salvo G, Rosato A, Guarneri V, Conte P. 129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
5
|
Cenci-Goga B, Amicabile A, Karama M, El-Ashram S, Saraiva C, García-Díez J, Finotti S, Genna V, Moretti G, Murari R, Muliari R, Bonizzato S, Lugoboni E, Cassini S, Dal-Ben C, Grispoldi L. Effect of Delayed Refrigeration on the Microbial Carcass Contamination of Wild Boars ( Sus scrofa). Animals (Basel) 2021; 11:ani11051434. [PMID: 34067688 PMCID: PMC8156622 DOI: 10.3390/ani11051434] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Revised: 05/10/2021] [Accepted: 05/13/2021] [Indexed: 11/24/2022] Open
Abstract
Simple Summary The bacteria that contaminate meat after the death of the animal can come from multiple sources, such as the animal itself, the external environment and the operator who handles it. The prompt refrigeration of hunted game is generally considered an important step to prevent spoilage and meat alterations, although many logistic hindrances, such as animal weight and distance from the hunting area to the refrigerators, limit the meticulous adoption of the best procedures. We show that the bacterial population of wild boar carcasses is not correlated to the mere time from shot to refrigeration but is correlated to the refrigeration time from chilling to analysis. The results of our study revealed a correlation between the time from shot to analysis and from refrigeration to analysis but a lack of correlation between the time from shot to refrigeration. Abstract The immediate refrigeration of meat after slaughter is a key issue for the proper storage and aging of meat. The industry standard cold chain relies on low temperatures and ventilation to lower the internal carcass temperature to 0–4 °C within the first 48 h, i.e., within four times the so-called semi-cooling time. On the other hand, for games, once bled and eviscerated, the carcass must be sent to a point where it can be sectioned or kept on air for maturation at refrigeration temperature. The precautions to observe are few and simple but essential: protect the meat and start the cooling process quickly. After preparing the animal (bleeding and evisceration), it may be necessary to face a period of transport that is sometimes long and not very easy; while small animals can be easily transported in a backpack, larger ones must necessarily be carried by several people or sometimes dragged to the vehicle capable of transporting them. It is obvious that a wild boar opened from the jaws to the pelvis and dragged for hundreds of meters will tend to be contaminated, although these contaminations are to be considered secondary for the preservation of the meat, compared to contamination by the intestinal contents. In an attempt to investigate the effect of delayed refrigeration on wild boar carcass contamination, the aim of this work was to determine a correlation between several hunting and logistic parameters (age, sex, animal weight, shooting distance, number of shots, weather and temperature and time from shot to refrigeration and to analysis) and bacterial contamination of the carcass. The correlation coefficient, r, was found to be 0.038 for the eviscerated body weight (p < 0.05), 0.091 for the external temperature on the day of hunting (p < 0.05), 0.027 for the time from shot to refrigeration (p = 0.081), 0.038 for the time from refrigeration to analysis (p < 0.05) and 0.043 for the time from shot to analysis (p < 0.05). These results stand for a negative correlation between the bacterial population and eviscerated carcass weight and between the bacterial population and external temperature and for a positive correlation between the time from shot to analysis and from refrigeration to analysis. No association was demonstrated between the bacterial population and the time from shot to refrigeration.
Collapse
Affiliation(s)
- Beniamino Cenci-Goga
- Dipartimento di Medicina Veterinaria, Università degli Studi di Perugia, 06126 Perugia, Italy;
- Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Onderstepoort 0110, South Africa;
- Correspondence:
| | - Alberto Amicabile
- Azienda Ulss 9 Scaligera—Via Valverde, 42-37122 Verona, Italy; (A.A.); (S.F.); (V.G.); (G.M.); (R.M.)
| | - Musafiri Karama
- Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Onderstepoort 0110, South Africa;
| | - Saeed El-Ashram
- School of Life Science and Engineering, Foshan University, Foshan 528231, China;
- Faculty of Science, Kafrelsheikh University, Kafr el-Sheikh 33516, Egypt
| | - Cristina Saraiva
- Department of Veterinary Sciences, School of Agrarian and Veterinary Sciences, University of Trás-os-Montes e Alto Douro, 5000-801 Vila Real, Portugal;
- Veterinary and Animal Research Centre (CECAV), University of Trás-os-Montes e Alto Douro, 5001-801 Vila Real, Portugal;
| | - Juan García-Díez
- Veterinary and Animal Research Centre (CECAV), University of Trás-os-Montes e Alto Douro, 5001-801 Vila Real, Portugal;
| | - Simone Finotti
- Azienda Ulss 9 Scaligera—Via Valverde, 42-37122 Verona, Italy; (A.A.); (S.F.); (V.G.); (G.M.); (R.M.)
| | - Viviana Genna
- Azienda Ulss 9 Scaligera—Via Valverde, 42-37122 Verona, Italy; (A.A.); (S.F.); (V.G.); (G.M.); (R.M.)
| | - Giampaolo Moretti
- Azienda Ulss 9 Scaligera—Via Valverde, 42-37122 Verona, Italy; (A.A.); (S.F.); (V.G.); (G.M.); (R.M.)
| | - Riccardo Murari
- Azienda Ulss 9 Scaligera—Via Valverde, 42-37122 Verona, Italy; (A.A.); (S.F.); (V.G.); (G.M.); (R.M.)
| | - Riccardo Muliari
- Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe)—Sezione di Verona—Via S. Giacomo, 5-37135 Verona, Italy; (R.M.); (S.B.); (E.L.); (S.C.); (C.D.-B.)
| | - Sabrina Bonizzato
- Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe)—Sezione di Verona—Via S. Giacomo, 5-37135 Verona, Italy; (R.M.); (S.B.); (E.L.); (S.C.); (C.D.-B.)
| | - Erica Lugoboni
- Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe)—Sezione di Verona—Via S. Giacomo, 5-37135 Verona, Italy; (R.M.); (S.B.); (E.L.); (S.C.); (C.D.-B.)
| | - Sabina Cassini
- Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe)—Sezione di Verona—Via S. Giacomo, 5-37135 Verona, Italy; (R.M.); (S.B.); (E.L.); (S.C.); (C.D.-B.)
| | - Caterina Dal-Ben
- Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe)—Sezione di Verona—Via S. Giacomo, 5-37135 Verona, Italy; (R.M.); (S.B.); (E.L.); (S.C.); (C.D.-B.)
| | - Luca Grispoldi
- Dipartimento di Medicina Veterinaria, Università degli Studi di Perugia, 06126 Perugia, Italy;
| |
Collapse
|
6
|
Sîrbu ID, Moretti G, Bortolotti G, Bolignari M, Diré S, Fambri L, Vertechy R, Fontana M. Electrostatic bellow muscle actuators and energy harvesters that stack up. Sci Robot 2021; 6:6/51/eaaz5796. [PMID: 34043528 DOI: 10.1126/scirobotics.aaz5796] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Accepted: 01/25/2021] [Indexed: 12/12/2022]
Abstract
Future robotic systems will be pervasive technologies operating autonomously in unknown spaces that are shared with humans. Such complex interactions make it compulsory for them to be lightweight, soft, and efficient in a way to guarantee safety, robustness, and long-term operation. Such a set of qualities can be achieved using soft multipurpose systems that combine, integrate, and commute between conventional electromechanical and fluidic drives, as well as harvest energy during inactive actuation phases for increased energy efficiency. Here, we present an electrostatic actuator made of thin films and liquid dielectrics combined with rigid polymeric stiffening elements to form a circular electrostatic bellow muscle (EBM) unit capable of out-of-plane contraction. These units are easy to manufacture and can be arranged in arrays and stacks, which can be used as a contractile artificial muscle, as a pump for fluid-driven soft robots, or as an energy harvester. As an artificial muscle, EBMs of 20 to 40 millimeters in diameter can exert forces of up to 6 newtons, lift loads over a hundred times their own weight, and reach contractions of over 40% with strain rates over 1200% per second, with a bandwidth over 10 hertz. As a pump driver, these EBMs produce flow rates of up to 0.63 liters per minute and maximum pressure head of 6 kilopascals, whereas as generator, they reach a conversion efficiency close to 20%. The compact shape, low cost, simple assembling procedure, high reliability, and large contractions make the EBM a promising technology for high-performance robotic systems.
Collapse
Affiliation(s)
- I D Sîrbu
- Department of Industrial Engineering, University of Trento, Trento, Italy
| | - G Moretti
- TeCIP Institute, Scuola Superiore Sant'Anna, Pisa, Italy
| | - G Bortolotti
- Department of Industrial Engineering, University of Trento, Trento, Italy
| | - M Bolignari
- Department of Industrial Engineering, University of Trento, Trento, Italy
| | - S Diré
- Department of Industrial Engineering, University of Trento, Trento, Italy
| | - L Fambri
- Department of Industrial Engineering, University of Trento, Trento, Italy
| | - R Vertechy
- Department of Industrial Engineering, University of Bologna, Bologna, Italy
| | - M Fontana
- Department of Industrial Engineering, University of Trento, Trento, Italy. .,TeCIP Institute, Scuola Superiore Sant'Anna, Pisa, Italy
| |
Collapse
|
7
|
Bivona U, Villalobos D, De Luca M, Zilli F, Ferri G, Lucatello S, Iannetti M, Cellupica L, Mungiello F, Lo Sterzo P, Marchegiani V, Puccitti A, Lombardi G, Moretti G, Donvito T, Penza F, Formisano R. Psychological status and role of caregivers in the neuro-rehabilitation of patients with severe Acquired Brain Injury (ABI). Brain Inj 2020; 34:1714-1722. [PMID: 33190555 DOI: 10.1080/02699052.2020.1812002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To investigate the relationships between (a) the psychological status of the caregiver, (b) the specific features of caregiving as perceived by the cognitive therapist in neuro-rehabilitation, (c) the caregivers' subjective approach to neuro-rehabilitation, and (d) the functional outcome of the patient. METHODS Twenty-four patients with severe acquired brain injury and their 24 caregivers participated in this observational study. Caregivers underwent a psychological assessment examining emotional distress, burden and family strain; their subjective approach to neuro-rehabilitation has been evaluated by two specific answers. The patients' cognitive therapists responded to an ad-hoc questionnaire, namely the "Caregiving Impact on Neuro-Rehabilitation Scale" (CINRS), evaluating the features (i.e., amount and quality) of caregiving. Finally, the functional outcome of the patient was assessed through standardized scales of disability and cognitive functioning. RESULTS The caregivers' psychological well-being was associated to the features of caregiving, to the subjective approach to neuro-rehabilitation, and to the functional recovery of their loved ones. A better caregivers' approach to neuro-rehabilitation was also associated to an overall positive impact of caregiving in neuro-rehabilitation and to a better functional outcome of the patients. CONCLUSIONS We posited a virtuous circle involving caregivers within the neuro-rehabilitation process, according to which the caregivers' psychological well-being could be strictly associated to a better level of caregiving and to a better functional outcome of the patients that, in turn, could positively influence the caregivers' psychological well-being. Although preliminary, these results suggest a specific psycho-educational intervention, aimed at improving the caregivers' psychological well-being and at facilitating their caring of the loved one.
Collapse
Affiliation(s)
- U Bivona
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - D Villalobos
- Laboratory of Cognitive and Computational Neuroscience. Center for Biomedical Technology (Technical University of Madrid and Complutense University of Madrid), Madrid, Spain
| | - M De Luca
- Neuropsychology Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - F Zilli
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - G Ferri
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - S Lucatello
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - M Iannetti
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - L Cellupica
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - F Mungiello
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - P Lo Sterzo
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - V Marchegiani
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - A Puccitti
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - G Lombardi
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - G Moretti
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - T Donvito
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - F Penza
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| | - R Formisano
- Post-Coma Unit, IRCCS Fondazione Santa Lucia, Rome, Italy
| |
Collapse
|
8
|
Dieci M, Guarneri V, Bisagni G, Tosi A, Musolino A, Spazzapan S, Moretti G, Vernaci G, Giarratano T, Lo Mele M, Rosato A, De Salvo G, Conte P. 162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.284] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Guarneri V, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, Orvieto E, Urso L, Pascual T, Paré L, Galván P, Ambroggi M, Giorgi CA, Moretti G, Griguolo G, Vicini R, Prat A, Conte PF. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann Oncol 2020; 30:921-926. [PMID: 30778520 PMCID: PMC6594455 DOI: 10.1093/annonc/mdz055] [Citation(s) in RCA: 58] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response (pCR) rates in hormone receptor (HR) positive versus negative tumors. The PerELISA study was aimed to evaluate the efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in HR+/HER2+ breast cancer patients selected on the basis of Ki67 inhibition after 2-week letrozole. PATIENTS AND METHODS PerELISA is a phase II, multicentric study for postmenopausal patients with HR+/HER2+ operable breast cancer. Patients received 2-week letrozole, and then underwent re-biopsy for Ki67 evaluation. Patients classified as molecular responders (Ki67 relative reduction >20% from baseline) continued letrozole and started trastuzumab-pertuzumab for five cycles. Patients classified as molecular non-responders started weekly paclitaxel for 13 weeks combined with trastuzumab-pertuzumab. Primary aim was breast and axillary pCR. According to a two-stage Simon's design, to reject the null hypothesis, at least 8/43 pCR had to be documented. RESULTS Sixty-four patients were enrolled, 44 were classified as molecular responders. All these patients completed the assigned treatment with letrozole-trastuzumab-pertuzumab and underwent surgery. A pCR was observed in 9/44 cases (20.5%, 95% confidence interval 11.1% to 34.5%). Among molecular non-responders, 16/17 completed treatment and underwent surgery, with pCR observed in 81.3% of the cases. PAM50 intrinsic subtype was significantly associated with Ki67 response and pCR. Among molecular responders, the pCR rate was significantly higher in HER2-enriched than in other subtypes (45.5% versus 13.8%, P = 0.042). CONCLUSIONS The primary end point of the study was met, by reaching the pre-specified pCRs. In patients selected using Ki67 reduction after short-term letrozole exposure, a meaningful pCR rate can be achieved without chemotherapy. PAM50 intrinsic subtyping further refines our ability to identify a subset of patients for whom chemotherapy might be spared. EUDRACT NUMBER 2013-002662-40. CLINICALTRIALS.GOV IDENTIFIER NCT02411344.
Collapse
Affiliation(s)
- V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova.
| | - M V Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova
| | - G Bisagni
- Department of Oncology and Advanced Technologies, Oncology Unit, Azienda USL-IRCCS di Reggio Emilia
| | - A Frassoldati
- Clinical Oncology, Department of Morphology, Surgery and Experimental Medicine, S Anna University Hospital, Ferrara
| | - G V Bianchi
- Medical Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
| | - G L De Salvo
- Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto IOV - IRCCS, Padova
| | - E Orvieto
- Pathology Unit, Azienda ULSS 5 Polesana, Rovigo, Italy
| | - L Urso
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova
| | - T Pascual
- Department of Medical Oncology, Hospital Clinic, Barcelona; Translational Genomics and Targeted Therapeutics in Solid Tumours Lab, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - L Paré
- Department of Medical Oncology, Hospital Clinic, Barcelona; Translational Genomics and Targeted Therapeutics in Solid Tumours Lab, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - P Galván
- Department of Medical Oncology, Hospital Clinic, Barcelona; Translational Genomics and Targeted Therapeutics in Solid Tumours Lab, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - M Ambroggi
- Department of Oncology-Hematology, Ospedale "G. da Saliceto", Piacenza
| | - C A Giorgi
- Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova
| | - G Moretti
- Department of Oncology and Advanced Technologies, Oncology Unit, Azienda USL-IRCCS di Reggio Emilia
| | - G Griguolo
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova; Translational Genomics and Targeted Therapeutics in Solid Tumours Lab, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - R Vicini
- Department of Diagnostic and Clinical Medicine and Public Health, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy
| | - A Prat
- Department of Medical Oncology, Hospital Clinic, Barcelona; Translational Genomics and Targeted Therapeutics in Solid Tumours Lab, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - P F Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova
| |
Collapse
|
10
|
Pasquini M, Fabbrini G, Moretti G, Berardelli I, Mandarelli G, Chiaie RD, Leone C, Biondi M, Berardelli A. Bradykinesia and Mental Slowness in Patients with Obsessive-compulsive Disorder. Eur Psychiatry 2020. [DOI: 10.1016/s0924-9338(09)71268-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Background:Clinical and experimental findings suggest that Obsessive-Compulsive Disorder (OCD) is due to an abnormality of the cortico-striato-thalamo-cortical circuit. Bradykinesia and mental slowness can be present in patients with basal ganglia disorders affecting the cortico-striato-thalamo-cortical circuit. Aim of this study is to investigate whether bradykinesia and mental slowness are present in patients with OCD.Methods:Participants comprised 19 non-depressed anti-psychotic free patients with OCD.Bradykinesia was assessed with the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS). Mental slowness was investigated with the WAIS-R and the Y-BOCS. Psychiatric evaluation was performed with: SCID-I, Y-BOCS, HAMD, HAM-A, and MMPI. Cognitive functions were assessed with the WAIS-R.Results:Bradykinesia and mental slowness were present respectively in the 39% and 89% of the patients. Bradykinesia was positively correlated to Y-BOCS mental slowness score (rho=0.48, p< 0.05), and inversely related to the WAIS-R Performance IQ score (rho=-0.65, p< 0.01). Patients with bradykinesia scored significantly lower in the Similarities and Digit symbol coding WAIS-R subscales as compared to non-bradykinetic patients. in our sample pathological doubt was not associated with IQ measures nor with bradykinesia. Twelve out of 19 patients (63%) showed impairments in the nonverbal function scores.Conclusions:The novel findings of this study is that bradykinesia can be present in patients with OCD, and it is correlated with mental slowness and nonverbal performance impairment. These preliminary data support the notion that dysfunction of basal ganglia is possibly present in OCD patients.
Collapse
|
11
|
Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. Ann Oncol 2019; 29:2328-2333. [PMID: 30219886 DOI: 10.1093/annonc/mdy414] [Citation(s) in RCA: 100] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age ≤35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR) <1.29 was chosen as the non-inferiority margin. Analyses according to the frequentist and Bayesian approach were planned. Secondary end points included 2-year failure rate and cardiac safety. Results A total of 1254 patients from 82 centers were randomized (arm A, long: n = 627; arm B, short: n = 626). Five-year DFS is 88% in the long and 85% in the short arm. The HR is 1.13 (90% CI 0.89-1.42), with the upper limit of the CI crossing the non-inferiority margin. According to the Bayesian analysis, the probability that the short arm is non-inferior to the long one is 80%. The 5-year overall survival (OS) is 95.2% in the long and 95.0% in the short arm (HR 1.07, 90% CI 0.74-1.56). Cardiac events are significantly lower in the short arm (risk-ratio 0.33, 95% CI 0.22-0.50, P < 0.0001). Conclusions This study failed to show the non-inferiority of a shorter trastuzumab administration. One-year trastuzumab remains the standard. However, a 9-week administration decreases the risk of severe cardiac toxicity and can be an option for patients with cardiac events during treatment and for those with a low risk of relapse. Trial Registration EUDRACT number: 2007-004326-25; NCI ClinicalTrials.gov number: NCT00629278.
Collapse
Affiliation(s)
- P Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto (IOV), IRCCS, Padova, Italy.
| | - A Frassoldati
- Clinical Oncology, Department of Morphology, Surgery and Experimental Medicine, S Anna University Hospital, Ferrara, Italy
| | - G Bisagni
- Department of Oncology and Advanced Technologies, Oncology Unit, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
| | - A A Brandes
- Medical Oncology, Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - M Donadio
- Department of Medical Oncology 1, Città della Salute e della Scienza Hospital, Turin, Italy
| | - O Garrone
- Medical Oncology, A.O. S. Croce and Carle Teaching Hospital, Cuneo, Italy
| | - F Piacentini
- Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
| | - L Cavanna
- Department of Oncology-Hematology, G. da Saliceto Hospital, Piacenza, Italy
| | - F Giotta
- Division of Medical Oncology, IRCCS, Giovanni Paolo II Hospital, Bari, Italy
| | - M Aieta
- Division of Medical Oncology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero Vulture (PZ), Italy
| | - V Gebbia
- Medical Oncology, Casa di Cura La Maddalena, University of Palermo, Palermo, Italy
| | - A Molino
- Oncology Unit, Verona University Hospital, Verona, Italy
| | - A Musolino
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - A Ferro
- Medical Oncology, Santa Chiara Hospital, Trento, Italy
| | - R Maltoni
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy
| | - S Danese
- Department of Gynecology and Obstetrics, Ospedale S. Anna, Turin, Italy
| | - C Zamagni
- Policlinico S.Orsola-Malpighi, SSD Oncologia Medica Addarii, Bologna, Italy
| | - A Rimanti
- Medical Oncology, Azienda Ospedaliera Carlo Poma, Mantova, Italy
| | - K Cagossi
- Division of Medical Oncology, "B.Ramazzini" Hospital, Carpi, Italy
| | - A Russo
- Section of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy
| | - P Pronzato
- Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS AOU San Martino-IST, Genova, Italy
| | - F Giovanardi
- Department of Oncology and Advanced Technologies, Oncology Unit, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
| | - G Moretti
- Department of Oncology and Advanced Technologies, Oncology Unit, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
| | - L Lombardo
- Medical Oncology, Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - A Schirone
- Clinical Oncology, Department of Morphology, Surgery and Experimental Medicine, S Anna University Hospital, Ferrara, Italy
| | - A Beano
- Department of Medical Oncology 1, Città della Salute e della Scienza Hospital, Turin, Italy
| | - L Amaducci
- Medical Oncology Unit, Ospedale degli Infermi Faenza, Faenza, Italy
| | - E A Bajardi
- Medical Oncology, Casa di Cura La Maddalena, University of Palermo, Palermo, Italy
| | - R Vicini
- Department of Diagnostic and Clinical Medicine and Public Health, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy
| | - S Balduzzi
- Department of Diagnostic and Clinical Medicine and Public Health, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy
| | - R D'Amico
- Azienda Ospedaliero-Universitaria di Modena, Modena, Italy; Department of Diagnostic and Clinical Medicine and Public Health, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto (IOV), IRCCS, Padova, Italy
| |
Collapse
|
12
|
Bossi P, Merlano M, Ghi M, Rinaldi G, Caponigro F, Morelli F, Airoldi M, Farnesi A, Cassano A, Ferrari D, Mirabile A, Tosoni A, Galizia D, Moretti G, Sponghini A, Calareso G, Vingiani A, Perrone F, Falletta A, Licitra L. A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz252.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Moretti G, Birettoni F, Caivano D, Nannarone S, Crovace A, Porciello F, Bufalari A. Mini-invasive approach for removal of iliopsoas migrating grass awns with an atraumatic wound retractor. J Small Anim Pract 2019; 62:150-155. [PMID: 31512264 DOI: 10.1111/jsap.13066] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 12/11/2018] [Accepted: 12/27/2018] [Indexed: 11/29/2022]
Abstract
This case series describes a novel mini coeliotomy approach using a radial, atraumatic self-retaining retractor for the retrieval of migrant plant foreign bodies from the iliopsoas muscles of six male dogs under intra-operative ultrasonographic guidance. Four dogs had a history of pulmonary disease potentially compatible with inhalation of a foreign body approximately 2-4 months before presentation. Under ultrasonographic guidance, the grass awns were identified in the iliopsoas muscle and were completely removed. In this case series, the annular ring device provided an excellent view of the surgical field for intra-abdominal manipulations. Patient follow-up at 15 days and 6 to 12 months after surgery indicated a full recovery, and no grass awn fragment residues were identified.
Collapse
Affiliation(s)
- G Moretti
- Department of Veterinary Medicine, University of Perugia, Via S. Costanzo n.4 (PG), 06126, Italy
| | - F Birettoni
- Department of Veterinary Medicine, University of Perugia, Via S. Costanzo n.4 (PG), 06126, Italy
| | - D Caivano
- Department of Veterinary Medicine, University of Perugia, Via S. Costanzo n.4 (PG), 06126, Italy
| | - S Nannarone
- Department of Veterinary Medicine, University of Perugia, Via S. Costanzo n.4 (PG), 06126, Italy
| | - A Crovace
- Department of Veterinary Medicine, University of Perugia, Via S. Costanzo n.4 (PG), 06126, Italy
| | - F Porciello
- Department of Veterinary Medicine, University of Perugia, Via S. Costanzo n.4 (PG), 06126, Italy
| | - A Bufalari
- Department of Veterinary Medicine, University of Perugia, Via S. Costanzo n.4 (PG), 06126, Italy
| |
Collapse
|
14
|
Sadeghi B, Remberger M, Gustafsson B, Winiarski J, Moretti G, Khoein B, Kingspor L, Westgren M, Mattsson J, Ringden O. Long-term follow up of a pilot study using placenta derived decidua stromal cells for severe acute graft versus host diseases. Cytotherapy 2019. [DOI: 10.1016/j.jcyt.2019.03.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Baroni S, Troiani E, Santonocito C, Moretti G, De Luca C, Antenucci M, Urbani A. A false positive case of high-sensitivity cardiac troponin in a patient with acute chest pain: Analytical study of the interference. Clin Biochem 2019; 66:103-105. [PMID: 30738031 DOI: 10.1016/j.clinbiochem.2019.02.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Revised: 01/29/2019] [Accepted: 02/03/2019] [Indexed: 11/27/2022]
Abstract
We report a case of a heterophile antibodies interference in a new high-sensitivity troponin commercial immunoassay (cTNIH Siemens), observed in a patient with possible acute coronary syndrome (ACS). The analytical interference was investigated with standard laboratories procedures. The false positive result was found with different troponin methods and kits. We also investigated the protein sequence of cTnl and no sequence variants were detected. The discordance between clinical pictures and high concentration of cTnl, together with the collaboration between clinicians and laboratory staff avoided possible erroneous diagnosis and further invasive investigations to the patient.
Collapse
Affiliation(s)
- S Baroni
- UOC Chimica, Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Università Cattolica del Sacro Cuore, Roma, Italy.
| | - E Troiani
- Università Cattolica del Sacro Cuore, Roma, Italy
| | - C Santonocito
- UOC Chimica, Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Università Cattolica del Sacro Cuore, Roma, Italy
| | - G Moretti
- Università Cattolica del Sacro Cuore, Roma, Italy
| | - C De Luca
- Università Cattolica del Sacro Cuore, Roma, Italy
| | - M Antenucci
- UOC Chimica, Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
| | - A Urbani
- UOC Chimica, Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; Università Cattolica del Sacro Cuore, Roma, Italy
| |
Collapse
|
16
|
Fortunato M, Berta L, Colleoni P, Sonzogni M, Moretti G. 144. Metric for assessment of mechanical reproducibility of leaves positions during VMAT treatment. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
17
|
Masini C, Berselli A, Banzi M, Bonelli C, Romagnani A, Pagano M, Damato A, Prati G, Gasparini E, Moretti G, Lorenzetti I, Zanelli F, Iachetta F, Pinto C. Correlation, in a real-world setting, between clinical-disease characteristics and compliance with immunotherapy in solid metastatic tumors: First results of an Italian CORE-IMMUNO study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Sadeghi B, Moretti G, Khoein B, Kamhieh-Milz J, Catar R, Geissler S, Moll G, Ringden O. Preclinical toxicity evaluation of therapeutic placenta-derived decidual stromal cells supported by anti-thrombin therapy. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
19
|
Boni C, Moretti G, Savoldi L, Armaroli L, Barbieri W, Bisagni G, Caroggio A, Iotti C, Pedroni C, Manenti AL, Rondini E, Sassi M, Zadro A. Neoadjuvant Chemotherapy with Continuous Infusion of Cisplatin and Fluorouracil in Stage II-IV, M0 Squamous Cell Carcinoma of the Head and Neck. Tumori 2018; 82:567-72. [PMID: 9061065 DOI: 10.1177/030089169608200610] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and Background The aim of the study was to assess the activity and the toxicity of cisplatin (DDP) and fluorouracil (FU) administered by continuous infusion as neoadjuvant chemotherapy for patients with stage II-IV, MO squamous cell carcinoma of the head and neck. Methods Thirty previously untreated patients were submitted to chemotherapy with DDP (20 mg/m2) and FU (1000 mg/m2), both in continuous infusion for 5 days, repeated every 21 days, for a maximum of 5 cycles. Following completion of chemotherapy, the patients underwent radiotherapy; in some patients surgery was performed immediately after chemotherapy. All patients were monitored for response, time to failure, survival, treatment-related events and toxicity. Results All patients were evaluated for response; after chemotherapy the complete response rate was 27% and the partial response rate 33%. Twenty-four patients underwent radiotherapy: the overall response rate was 83% (complete response 79%). After a median follow-up of 34 months, the median survival time was 22 months with a median time to failure of 15 months. Acute vascular accidents were the main and unexpected adverse events, with 2 deaths for pulmonary embolism and 1 for stroke. The response rate to the regimen does not seem to be better than that obtained with the standard combination of cisplatin bolus and fluorouracil continuous infusion. The disadvantage of the regimen is that it causes more discomfort for the patient in that it requires hospitalization. Conclusions For this reason, we believe that there are no elements for recommending the schedule as neoadjuvant treatment of patients with squamous cell carcinoma of the head and neck or as an experimental arm in a randomized trial.
Collapse
Affiliation(s)
- C Boni
- Servizio di Oncologia Medica, Azienda Ospedaliera di Reggio Emilia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Bisagni G, Boni C, Manenti AL, Moretti G, Rondini E, Sassi M, Zadro A, Savoldi L. Ifosfamide Bolus Followed by Five Days Continuous Infusion in Extensively Pretreated Patients with Advanced Breast Cancer: A Phase II Study. Tumori 2018; 84:659-61. [PMID: 10080671 DOI: 10.1177/030089169808400608] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE A phase II study with ifosfamide in pretreated patients with advanced breast cancer was performed to determine the objective response rate, the toxicity and the feasibility of the regimen. METHODS & STUDY DESIGN Patients enrolled had advanced breast cancer pretreated with at least one previous regimen of chemotherapy for advanced disease. Treatment consisted of ifosfamide infused at a dose of 2 g/m2 iv in 4 hrs followed by ifosfamide, 8 g/m2 iv in 120 hrs in ambulatory treatment, using a portable external pump system. The total dose of ifosfamide was 10 g/m2; mesna (4 g/m2 iv) was administered mixed with ifosfamide in 120 hrs Cycles were repeated every 3 weeks. Three patients were pretreated with neoadjuvant and 15 with adjuvant chemotherapy. All patients were treated for advanced disease (median number of regimens, 1; range, 1-3): 21 with the cyclophosphamide-containing regimen and 15 with adryamicin. Sixteen patients received one or more lines of endocrine therapy. Fifteen patients had dominant site in viscera, 6 in bone, and only one in soft tissue; 17 patients had more than one site of disease. RESULTS Twenty-two patients were enrolled and all were assessable for response and toxicity. A partial response was reached in 5 patients (23%; 95% confidence limits 5% to 60%). Hematologic toxicity was the dose-limiting side effect; grade 4 leukopenia occurred in 10 patients (46%). CONCLUSIONS Considering the response rate obtained in our series of intensively pretreated patients, the results seem to indicate that the regimen is active and could be included among the possible options in the treatment of patients with refractory, poor-prognosis, advanced breast carcinoma.
Collapse
Affiliation(s)
- G Bisagni
- Medical Oncology Service, General Hospital, Reggio Emilia, Italy
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Russo P, Papa V, Russo S, Bella AD, Pabst G, Milazzo G, Balestrazzi A, Caporossi A, Anselmetti G, Lorenzi U, Orsi R, Faletti P, Bindella G, Boccassini G, Kropp B, Calabria G, Campagna P, Ciurlo C, Caporossi A, Tasciotti A, Licignano R, Balestrazzi A, Caprioglio G, Birattari F, Franch A, Darondeau J, Blanluet G, Ouen S, Guerra R, Saccarola P, Lenz W, Schuff O, Lùpidi G, Coiràn M, Checcucci M, Burattini L, Foligno, Mastropasqua L, Ciancaglini M, Ciafrè M, Cerulli A, Moretti G, Padovano S, Rotondo SG, Neuhann T, Okrafka K, Ratiglia R, Oldani A, Reiss H, Rochefort J, Coulombe B, Sborgia C, Lorusso V, Palmisano C, Moramarco N, Spinelli D, Curatola M, Maruccia A, Vaona P, Faraldi F, Villani C, Schiavone M, Gisoldi RC. Topical Nonsteroidal Anti-Inflammatory Drugs in Uncomplicated Cataract Surgery: Effect of Sodium Naproxen. Eur J Ophthalmol 2018. [DOI: 10.1177/112067210501500510] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose To investigate whether topical nonsteroidal anti inflammatory drugs (NSAIDs) are useful, in the absence of concomitant corticosteroid therapy, in limiting postoperative inflammation after uncomplicated cataract surgery. Methods A total of 328 patients were enrolled in a prospective, randomized, double-masked, parallel-group, active-controlled study. Anterior chamber inflammation (ACI) was evaluated as the primary efficacy parameter. Only patients with moderate inflammation (ACI score of ≤4) the day after surgery were randomized and treated with NSAIDs. A novel topical formulation containing 0.2% sodium naproxen was compared with 0.1% diclofenac. Both were administered three times a day for 14 consecutive days. Ocular inflammation was measured after 7 and 14 days by using slit-lamp biomicroscopy. Safety parameters were also evaluated at the same time. Results Both treatments were equally effective in controlling postsurgical inflammation. No statistically significant differences between treatment groups were observed for the safety variables. No serious adverse events (AEs) occurred during the course of the study. The most frequent AE reported with naproxen was eye redness. Conclusions NSAIDs can effectively be used without concurrent administration of corticosteroids to control postoperative inflammation after uncomplicated cataract surgery. In addition, naproxen ophthalmic solution may be considered a suitable alternative to the currently available NSAIDs.
Collapse
Affiliation(s)
- P. Russo
- Medical Department SIFI SpA, Catania - Italy
| | - V. Papa
- Medical Department SIFI SpA, Catania - Italy
| | - S. Russo
- Medical Department SIFI SpA, Catania - Italy
| | - A. Dl Bella
- Medical Department SIFI SpA, Catania - Italy
| | - G. Pabst
- AAI Deutschland GmbH & Co KG, Neu-Ulm - Germany
| | - G. Milazzo
- Medical Department SIFI SpA, Catania - Italy
| | - A. Balestrazzi
- Department of Ophthalmology, University of Siena, Siena - Italy
| | - A. Caporossi
- Department of Ophthalmology, University of Siena, Siena - Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Bossi P, Miceli R, Locati LD, Ferrari D, Vecchio S, Moretti G, Denaro N, Caponigro F, Airoldi M, Moro C, Vaccher E, Sponghini A, Caldara A, Rinaldi G, Ferrau F, Nolè F, Lo Vullo S, Tettamanzi F, Hollander L, Licitra L. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2017; 28:2820-2826. [PMID: 28950305 DOI: 10.1093/annonc/mdx439] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/08/2023] Open
Abstract
BACKGROUND B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b, noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin with/without paclitaxel (CetCis versus CetCisPac) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). PATIENTS AND METHODS Eligible patients had confirmed R/M SCCHN (oral cavity/oropharynx/larynx/hypopharynx/paranasal sinus) and no prior therapy for R/M disease. Cetuximab was administered on day 1 (2-h infusion, 400 mg/m2), then weekly (1-h infusions, 250 mg/m2). Cisplatin was given as a 1-h infusion (CetCis arm: 100 mg/m2; CetCisPac arm: 75 mg/m2) on day 1 of each cycle for a maximum of six cycles. Paclitaxel was administered as a 3-h infusion (175 mg/m2) on day 1 of each cycle. After six cycles, maintenance cetuximab was administered until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). We assumed a noninferiority margin of 1.40 as compatible with efficacy. RESULTS A total of 201 patients were randomized 1 : 1 to each regimen; 191 were assessable. PFS with CetCis (median, 6 months) was noninferior to PFS with CetCisPac (median, 7 months) [HR for CetCis versus CetCisPac 0.99; 95% CI: 0.72-1.36, P = 0.906; margin of noninferiority (90% CI of 1.4) not reached]. Median overall survival was 13 versus 11 months (HR = 0.77; 95% CI: 0.53-1.11, P = 0.117). The overall response rates were 41.8% versus 51.7%, respectively (OR = 0.69; 95% CI: 0.38-1.20, P = 0.181). Grade ≥3 adverse event rates were 76% and 73% for CetCis versus CetCisPac, respectively, while grade 4 toxicities were lower in the two-drug versus three-drug arm (14% versus 33%, P = 0.015). No toxic death or sepsis were reported and cardiac events were negligible (1%). CONCLUSION The two-drug CetCis regimen proved to be noninferior in PFS to a three-drug combination with CetCisPac. The median OS of both regimens is comparable with that observed in EXTREME, while the life-threatening toxicity rate appeared reduced. CLINICAL TRIAL NUMBER EudraCT# 2011-002564-24.
Collapse
Affiliation(s)
- P Bossi
- Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan University of Milan, Milan
| | - R Miceli
- Clinical Epidemiology and Trial Organization, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
| | - L D Locati
- Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan University of Milan, Milan
| | - D Ferrari
- Medical Oncology, Ospedale San Paolo, Milan
| | - S Vecchio
- Medical Oncology, IRCCS San Martino, IST National Cancer Institute, Genova and University of Genova, Genova
| | - G Moretti
- Medical Oncology, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia
| | - N Denaro
- Medical Oncology, St. Croce & Carle University Teaching Hospital, and ARCO Foundation, Cuneo
| | - F Caponigro
- Medical Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Naples
| | - M Airoldi
- 2nd Medical Oncology Division, Città della Salute e della Scienza Hospital of Turin, Turin
| | - C Moro
- Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo
| | - E Vaccher
- Medical Oncology, Centro di Riferimento Oncologico, Aviano
| | - A Sponghini
- Medical Oncology, A.O. Universitaria Maggiore della Carità, Novara
| | - A Caldara
- Medical Oncology, Ospedale Santa Chiara, Trento
| | - G Rinaldi
- Medical Oncology, AOU Policlinico "Paolo Giaccone," Palermo
| | - F Ferrau
- Medical Oncology, Ospedale San Vincenzo, Taormina
| | - F Nolè
- Medical Oncology, Istituto Europeo di Oncologia, Milan
| | - S Lo Vullo
- Clinical Epidemiology and Trial Organization, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan
| | - F Tettamanzi
- Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - L Hollander
- Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - L Licitra
- Head and Neck Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan University of Milan, Milan.
| |
Collapse
|
23
|
Di Cicilia R, Garcia-Arias A, Berselli A, Gervasi E, Stridi G, Bonelli C, Romagnani A, Gnoni R, Bologna A, Moretti G, Bologna A, Pinto C. Eribulin mesylate in advanced breast cancer: retrospective review of a single institution experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Bossi P, Hollander L, Miceli R, Ferrari D, Vecchio S, Moretti G, Merlano M, Caponigro F, Moro C, Vaccher E, Alabisio O, Caldara A, Russo A, Ferrau F, Nolè F, Licitra L. First line cetuximab and cisplatin with or without paclitaxel in recurrent/metastatic head and neck cancer: A randomized phase IIb trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, Ficorella C, Frassoldati A, Fumagalli A, Garrone O, Gebbia V, Generali D, La Verde N, Maur M, Michelotti A, Moretti G, Musolino A, Palumbo R, Pistelli M, Porpiglia M, Sartori D, Scavelli C, Schirone A, Turletti A, Valerio MR, Vici P, Zambelli A, Clivio L, Torri V. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. Breast 2017; 35:115-121. [PMID: 28711793 DOI: 10.1016/j.breast.2017.06.043] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Revised: 06/12/2017] [Accepted: 06/29/2017] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. PATIENTS AND METHODS This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. RESULTS From July 2013 to December 2015, the EVA study enrolled 404 pts. Median age was 61 years (33-83). Main metastatic sites were: bone (69.1%), soft tissue (34.7%) and viscera (33.2%). Median number of previous treatments was 2 (1-7). 43.3% of the pts had received Fulvestrant. Median exposure to EVE was 31.0 weeks (15.4-58.3) in the whole population. No difference was observed in terms of EVE exposure duration according to DI (p for trend = 0.27) or type of previous treatments (p = 0.33). ORR and Disease Control Rate (DCR) were observed in 31.6% and 60.7% of the patients, respectively, with the lowest ORRs confined in CHT pre-treated patients or in those who received the lowest DI of EVE. Grade 3-4 adverse events (AEs) were reported in 37.9% of the patients. Main AEs were: stomatitis (11.2%), non-infectious pneumonitis - NIP (3.8%), anaemia (3.8%) and fatigue (3.2%). CONCLUSIONS The EVA study provided new insights in the use of EVE-EVE combination in HR+ ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.
Collapse
Affiliation(s)
- M E Cazzaniga
- Research Unit Phase I Trials, ASST Monza, Monza, Italy; Oncology Unit, ASST Monza, Monza, Italy.
| | - M Airoldi
- Oncology Unit 2 - Città della Salute e della Scienza di Torino, Torino, Italy
| | - V Arcangeli
- Oncology Unit Rimini Azienda USL Romagna, Rimini, Italy
| | - S Artale
- Oncology Department, Ospedale di Gallarate ASST Valle Olona, Gallarate, Italy
| | - F Atzori
- Oncology Unit, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy
| | - A Ballerio
- Oncology Unit, ASST della Valle Olona - Presidio Ospedaliero di Saronno, Saronno, Italy
| | - G V Bianchi
- Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - L Blasi
- Oncology Unit, ARNAS Civico Palermo, Palermo, Italy
| | - S Campidoglio
- Oncology Unit, Ospedale Sacro Cuore di Gesù, Fatebenefratelli, Benevento, Italy
| | - M Ciccarese
- Oncology Unit, Ospedale "Vito Fazzi" di Lecce, Lecce, Italy
| | - M C Cursano
- Oncology Unit, Università Campus Bio-Medico, Roma, Italy
| | - M Piezzo
- National Cancer Institute "Fondazione Giovanni Pascale", Napoli, Italy
| | - A Fabi
- Oncology Unit 1, Istituto Regina Elena - IFO, Roma, Italy
| | - L Ferrari
- Oncology Unit, ASL di Frosinone Osp. "SS. Trinità", Italy
| | - A Ferzi
- Oncology Unit, ASST OVEST Milanese - Presidio di Legnano, Legnano, Italy
| | - C Ficorella
- Dipartimento di Scienze Cliniche Applicate e Biotecnologiche (DISCAB) - Università Degli Studi Dell'Aquila, L'Aquila, Italy
| | - A Frassoldati
- Oncology Unit, Az Ospedaliero Universitaria di Ferrara, Ferrara, Italy
| | - A Fumagalli
- Oncology Unit, Ospedale Moriggia Pelascini, Gravedona, Italy
| | - O Garrone
- Oncology Unit, A.O. S. Croce e Carle Ospedale di Insegnamento, Cuneo, Italy
| | - V Gebbia
- Oncology Unit, Osp. La Maddalena, Palermo, Italy
| | | | - N La Verde
- Oncology Unit, ASST Fatebenefratelli Sacco, Milano, Italy
| | - M Maur
- Oncology and Haematology Department, A.O.U Policlinico di Modena, Modena, Italy
| | - A Michelotti
- Oncology Unit I, Ospedale S. Chiara, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - G Moretti
- Oncology Unit, IRCCS Arcispedale S. Maria Nuova, Reggio Emilia, Italy
| | - A Musolino
- Oncology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
| | - R Palumbo
- Oncology Unit, IRCCS ICS Maugeri, Pavia, Italy
| | - M Pistelli
- Oncology Unit, AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi, Ancona, Italy
| | - M Porpiglia
- Oncology Unit, Presidio Ospedaliero S. Anna, Torino, Italy
| | - D Sartori
- Oncology Unit, AULSS 3, Mirano, Italy
| | - C Scavelli
- Oncology Unit, Ospedale "S. Cuore di Gesù", Gallipoli, Italy
| | - A Schirone
- Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - A Turletti
- Oncology Unit, Ospedale Martini della ASL "Città di Torino", Torino, Italy
| | - M R Valerio
- Oncology Department, Policlinico di Palermo Paolo Giaccone, Palermo, Italy
| | - P Vici
- Oncology Unit, Istituto Nazionale Tumori Regina Elena - IFO, Roma, Italy
| | - A Zambelli
- Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - L Clivio
- IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy
| | - V Torri
- IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy
| | | | | |
Collapse
|
26
|
Torri V, Cazzaniga M, Galli F, Valerio M, Ficorella C, Garrone O, Palumbo R, Fumagalli A, Moretti G, De Laurentiis M, Frassoldati A, Artale S, Zambelli A, Vici P, Maur M, Sartori D, Fabi A. Efficacy and safety of everolimus (eve) and exemestane (exe) in postmenopausal hormone-receptor positive (hr+) advanced breast cancer (abc) patients (pts) beyond clinical trials: preliminary results of the observational multicenter eva study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Masini C, Bisagni G, Ragazzi M, Bisagni A, Dallaglio K, Falco G, Ferrari G, Bassano C, Gardini G, Bologna A, Moretti G, Boni C, Baldi L, Pinto C. Relationship between HER-2 amplification and tumor infiltrating lymphocytes in breast cancer patients treated with neoadjuvant trastuzumab. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Masini C, Bisagni A, Falco G, Bassano C, Baldi L, Bisagni G, Moretti G, Albini A, Boni C, Ferrari G, Gardini G. Relationship between levels of HER-2 amplification and pathologic complete response to trastuzumab-based neoadjuvant treatment. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Moretti G, Fierro G, Ferraris G, Andreozzi G, Naticchioni V. N2O decomposition over [Fe]-MFI catalysts: Influence of the Fe O nuclearity and the presence of framework aluminum on the catalytic activity. J Catal 2014. [DOI: 10.1016/j.jcat.2014.07.005] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
30
|
Difede G, Scalzo G, Bucchieri S, Moretti G, Campisi G, Napoli N, Battista Rini G, Guglielmi G. Underreported vertebral fractures in an Italian population: comparison of plain radiographs vs quantitative measurements. Radiol Med 2010; 115:1101-10. [PMID: 20680502 DOI: 10.1007/s11547-010-0554-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2009] [Accepted: 11/27/2009] [Indexed: 11/26/2022]
Abstract
PURPOSE Vertebral fractures (VFs) are the hallmark of osteoporosis and are responsible for almost 70,000 hospital admissions yearly, implying social costs and impaired quality of life for patients. In recent years, several techniques, both qualitative and quantitative, have been proposed for VF diagnosis, but a gold standard is not yet available and the visual semiquantitative (VSQ) assessment proposed by Genant remains the most validated. However, given the lack of a standardised method, in clinical practice, the diagnosis of VF is often missed, and patients are not correctly assessed. The aim of our study was to estimate the percentage of VFs not detected in clinical practice in italian population using the VSQ method and a new morphometric technique. MATERIALS AND METHODS In 283 postmenopausal women referred to our clinic for osteoporosis screening, we performed a clinical examination, plain spinal radiographs (for VSQ assessment) and digital computerised morphometry (DCM) to assess VFs. Bone density was measured using dual-energy X-ray absorptiometry (DXA). RESULTS Forty-seven percent of patients had a T score <-2.5 standard deviations (SD), and 35.2% were osteopenic, but no significant correlations between T score and grade or number of fractures were found. DCM identified VFs in 38.5% of patients versus 32.5% using the VSQ method. Overall, 280 VFs were detected by DCM and 236 by VSQ, whereas only 105 were recognised by the reports. CONCLUSIONS VFs went undetected in 55.5% according to the VSQ method on standard spinal radiographs. Therefore, the morphometric technique may be helpful when performed with the semiquantitative approach to improve recognition of VFs. However, other studies are needed to further validate the utility of this new morphometric technique in clinical practice.
Collapse
Affiliation(s)
- G Difede
- Department of Internal Medicine - Metabolic Bone Disease Unit, University of Palermo, Via Del Vespro 147, 90143 Palermo, Italy
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Pasquini M, Tarsitani L, Piacentino D, Moretti G, Roscioli C, Leone C, Biondi M. Patients' expectations for antidepressant treatment outcome. Psychother Psychosom 2010; 78:390-1. [PMID: 19738410 DOI: 10.1159/000235984] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
32
|
Macarini L, Milillo P, Cascavilla A, Scalzo G, Stoppino L, Vinci R, Moretti G, Ettorre G. MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers. Radiol Med 2009; 114:1267-82. [DOI: 10.1007/s11547-009-0464-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2008] [Accepted: 03/05/2009] [Indexed: 12/21/2022]
|
33
|
Cianficconi F, Sorcetti CC, Moretti G, Dallai R. Ultrastructural organization of the rectal pads in adultStenophylax permistusMcL. (Trichoptera). ACTA ACUST UNITED AC 2009. [DOI: 10.1080/11250008509440543] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
34
|
Dallai R, Moretti G, Cianficconi F, Sorcetti CC. Freeze-fracture study of the rectal pads inStenophylax permistusMcL. (Trichoptera). ACTA ACUST UNITED AC 2009. [DOI: 10.1080/11250008509440545] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
35
|
|
36
|
Mavilia L, Malara G, Moretti G, Lo Re M, Puglisi Guerra A. Photodynamic therapy of acne using methyl aminolaevulinate diluted to 4% together with low doses of red light. Br J Dermatol 2007; 157:810-1. [PMID: 17635510 DOI: 10.1111/j.1365-2133.2007.08074.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Vujinovic B, Arighi E, Botta F, Casartelli R, Moretti G, Pieretti B, Tettamanti B, Terramocci R. VALUTAZIONE “IN VITRO” DI TERRENI AGARIZZATI PER LA RILEVAZIONE DI CEPPI BATTERICI ESßL PRODUTTORI. Microbiol Med 2007. [DOI: 10.4081/mm.2007.2873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
38
|
Botta F, Arighi E, Casartelli R, Moretti G, Pieretti B, Tettamanti B, Terramocci R. VALUTAZIONE DELL’ATTIVITÀ ANTI-BATTERICA “IN VITRO” DELL’ULIFLOXACINA NEI CONFRONTI DEI PRINCIPALI BATTERI GRAM NEGATIVI UROPATOGENI. Microbiol Med 2007. [DOI: 10.4081/mm.2007.2750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
39
|
Paccagnella A, Michieletto S, Pitassi I, Baruffi C, Pizzolato D, Marcon ML, Saia OS, Toscani P, Moretti G, Foscolo G. [Organisational aspects of a donated breast milk bank: experience of the Treviso hospital]. Minerva Pediatr 2007; 59:337-348. [PMID: 17947840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
AIM This study analyses the organisational aspects and the volume of milk managed by the donated breast milk bank (banca del latte umano donato, BLUD) in Treviso. METHODS The data gathered refer to the years 2003, 2004 and 2005. In particular the hygiene methodology is described in order to obtain a high-quality product from a clinical point of view which is in line with the recent norms regarding the management of food products. RESULTS During the three-year study 5,647 L of milk were collected (on average: 155 L/month; 5 L/day). Seventy-two percent of breast milk collected was from mothers for their own children; the remaining 28% of milk was from ''donors for the pool''. In the same period 5,053 L of milk was pasteurised and distributed (pool=31%; frozen breast milk=61%; chilled unpasteurized breast milk =8%). Microbiological data show total effectiveness of the methods of pasteurisation used (Holder method). The tracking of the product is possible through the BLUD organisation. CONCLUSION We propose: 1) that scientific organisations and legislators try to optimise the control of this important product by providing guidelines, indications, microbiological parameters and legal obligations for the correct continuation of the work carried out by BLUDs; 2) that BLUDs create a network for rapid communication, integration and possible collaboration; 3) that a study be carried out regarding BLUDs and population density in order to balance costs and benefits.
Collapse
Affiliation(s)
- A Paccagnella
- Servizio di Dietetica e Nutrizione Clinica, Dipartimento di Medicina, ULSS 9, Treviso, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
|
41
|
Gori S, De Angelis V, Rimondini S, Mosconi AM, Moretti G, Bisagni G, Sidoni A, Aristei C, Franceschi E, Colozza M, Crino L. Incidence and risk factors for central nervous system (CNS) metastases in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10516 Background: Recently, an increased incidence of CNS metastases in HER2+ MBC has been reported. Aims of the observational study were to evaluate the incidence and risk for CNS metastases in HER2+ MBC pts. Methods: We reviewed the occurrence of CNS metastases in 122 consecutive HER2+ MBC pts treated with chemotherapy (CT) and trastuzumab (T)between April 1999 and June 2005. Patient characteristics included: median age 48 yrs (28–79); G3 in 58.1%;ER- in 53.2%; DFS <24 mos in 48.3% and ≥24 mos in 51.7%. Visceral metastatic disease was dominant site of relapse in 67.2% of the pts. T+CT represented the 1st line of treatment in 54% of pts, 2nd line in 28.6% and ≥3th line in 17.2%. Results: At median follow up of 28 mos (2–167) from the occurrence of metastatic disease, 43 pts (35.2%) developed CNS metastases, confirmed by CT or MRI scanning. In 42 pts were present one or more parenchymal brain metastases and in 1 pt leptomeningeal carcinomatosis. Neurological symptoms were present in 90% of pts. Out of the 43 pts developing CNS metastases, 37.2% were in response in other metastastic sites and CNS represented the only site of progression. Median time of occurrence of CNS metastases (from diagnosis of metastatic disease) was 12 mos (0–78).Using the presence/absence of CNS metastases as dependent variable in logistic regression analysis, we obtained that age (p = 0.020) and visceral metastases (p = 0.024) were significantly associated with increased risk of CNS metastases. Panencephalic RT was given in 31 out of 43 pts; 16 pts (37.2%) received T ± further CT and 18 pts (41.8%) only cytotoxic CT. Median OS was 51.2 mos (1.9+-167.4) in the all population. Median OS was 35 mos (4–105) in pts with CNS metastases; at the present analysis median OS has not been reached in pts without CNS metastases (p = 0.002). Conclusions: CNS metastases is common, late event in the natural history of HER2-positive MBC. Age and visceral metastases were significantly associated with increased risk for CNS metastases. Clinical trials are indicated to evaluate:1) any clinical, pathological and molecular risk factors for CNS metastases; 2) if there is indication to specific treatment in a population at high risk of CNS metastases. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Gori
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - V. De Angelis
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - S. Rimondini
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - A. M. Mosconi
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - G. Moretti
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - G. Bisagni
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - A. Sidoni
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - C. Aristei
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - E. Franceschi
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - M. Colozza
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| | - L. Crino
- Silvestrini Hospital, Perugia, Italy; Bellaria Hospital, Bologna, Italy; Reggio Emilia Hospital, Reggio Emilia, Italy; Perugia University, Perugia, Italy; Monteluce Hospital, Perugia, Italy
| |
Collapse
|
42
|
Moretti G, Ferraris G, Fierro G, Lo Jacono M. An XPS study of the reduction process of CuO–ZnO–Al2O3 catalysts obtained from hydroxycarbonate precursors. SURF INTERFACE ANAL 2006. [DOI: 10.1002/sia.2129] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
43
|
Kövér L, Kovács Z, Sanjinés R, Moretti G, Cserny I, Margaritondo G, Pálinkás J, Adachi H. Electronic structure of tin oxides: High-resolution study of XPS and Auger spectra. SURF INTERFACE ANAL 2004. [DOI: 10.1002/sia.740230705] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
|
45
|
Carati A, Ferraris G, Guidotti M, Moretti G, Psaro R, Rizzo C. Preparation and characterisation of mesoporous silica–alumina and silica–titania with a narrow pore size distribution. Catal Today 2003. [DOI: 10.1016/s0920-5861(02)00376-0] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
|
47
|
Romano R, Fattorini F, Ciccaglioni A, Rocco A, Moretti G, Cappelletti M, Pietropaoli P. Transesophageal atrial pacing in the management of re-entry supraventricular tachyarrhythmias occurring during general anesthesia. Minerva Anestesiol 2002; 68:825-9, 829-32. [PMID: 12538965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
BACKGROUND Supraventricular tachyarrhythmias (SVTs) represent an intraoperative risk factor that should be always prevented/managed. The commonly used anti-arrhythmic drugs are accompanied by intrinsic hazards, such as pro-arrhythmic and toxic effects or unpredictable onset and duration of action. We underline the therapeutic use of transesophageal atrial pacing (TAP) for the interruption of particular re-entry SVTs occurred during surgical procedures in general anaesthesia. METHODS Our study was carried out in 25 patients characterized by a personal clinical history of transient tachyarrhythmic episodes, subjected to general anaesthesia obtained by midazolam, propofol, N2O e O2, sevoflurane, fentanil and vecuronium bromide. We used TAP bursts of 3-5 sec, their minimal pacing rate being equivalent to the tachyarrhythmia cycle length, with an impulse intensity ranging from 18 to 25 mA. In such conditions, the re-entry was interrupted by the induction of refractoriness of the wave-front that sustained the underlying arrhythmogenic circuit. RESULTS During the study, the following arrhythmias occurred in 7 out of all patients: 1 type I atrial flutter, 3 nodal tachycardias, 1 antidromic and 2 orthodromic atrioventricular tachycardias, respectively. TAP assured either atrial capture or prompt suppression of arrhythmias in all cases. Low intensity impulses did not ever allow ventricular capture. CONCLUSIONS TAP can be considered as a valid therapeutic device for the management of re-entry SVTs occurred during general anaesthesia, resulting it effective, safe and easy-practicable.
Collapse
Affiliation(s)
- R Romano
- Department of Medical and Surgical Emergencies, University of Ancona, Ancona, Italy.
| | | | | | | | | | | | | |
Collapse
|
48
|
|
49
|
|
50
|
Castle JE, Salvi AM, Decker F, Moretti G. Use of the absolute Auger parameter for vanadium in the study of the dielectric relaxation of cerium vanadate. SURF INTERFACE ANAL 2002. [DOI: 10.1002/sia.1416] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|